1Lip GY, Tse HF(2007) Management of atrial fibrillation. Lancet 370: 604-618
2Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983-988.
3Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 147: 1561-1564.
4Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation -- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 48: 854-906.
5Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, et al. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S.
6Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131: 492-501.
7Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, (1999) Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 131: 927-934.
8 Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, et al. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290: 2685-2692.
9Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, et al. (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26:2422-2434.
10 BirmanDeych E, Radford MJ, Nilasena DS, Gage BF (2006) Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 37: 1070-1074.
11Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115: 2689-2696.
12Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P et al (2008). Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118: 2029-2037.
13Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15: 244-252.
14Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066-2078.
15Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
16Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
17Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, et al. (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806-817.
18Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-92.
19Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al. (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: 2093-2104.
20Boehringer Ingelheim Pharmaceuticals, Inc. ( 2012) Pradaxa (Dabigatran Etexilate Mesylate) Prescribing Information.
21US Food and Drug Administration (2011) FDA Drug Safety Communication: Safety Review of Post-Market Reports of Serious Bleeding Events with the Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate).
22Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15: 9S–16S.
23Van Ryn J, Hauel N, Waldmann L, Wienen W (2008) Dabigatran inhibits both clot-bound and fluid-phase thrombin in vitro: comparison to heparin and hirudin. Arterioscler Thromb Vasc Biol 28: e136–e137.
24Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 123: 1436–1450.
25Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292–303.
26Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, et al. (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157: 805-810.
27Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903-1912.
28Amadeus Investigators, Bousser MG, Bouthier J, Büller HR, Cohen AT, et al. (2008) Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371: 315-321.
29Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347: 969-974.
30Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146: 857-867.
31Mueck W, Stampfuss J, Kubitza D, Becka M (2013) Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clin Pharmacokinet 53: 1-16.
32Dewald TA, Becker RC (2013) The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 37: 217-233
33Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, et al. (2013) Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 8: 1533-1539.
34 ROCKET AF (2010) Study Investigators (2010) Rivaroxaban — once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159: 340-347.
35EINSTEIN–PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287-1297.
36Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, et al. (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358: 2776-86.
37Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, et al. (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358: 2765-75.
38Raghavan N, Frost CE, Yu Z, He K, Zhang H, et al. (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37: 74-81.
39Sehgal V, Bajwa SJ, Bajaj A (2013) New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly. Ann Card Anaesth 16: 193-200.
40Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, et al. (2010) Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 159: 348-353.
41Wyse DG, Slee A, Epstein AE, Gersh BJ, Rocco T Jr, et al. (2004) Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm 1: 531-537.
42Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147: 590-592.
43Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, et al. (2010) Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159: 331-339.
44Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3: 692-694.
45Matsushima N, Lee F, Sato T, Weiss D, Mendell J (2013) Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin. Pharm. Drug Dev 2: 358-66.
46Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, et al. (2010) Clinical safety, tolerability, pharmacokinetics, and Pharmacodynamics of the Novel factor Xa Inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50: 743-753.
47Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, et al. (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160: 635-641.
48Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, et al. (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369: 1206-1214.
49Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH (2012) American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e576S-600S.
50Aakre CA, McLeod CJ, Cha SS, Tsang TS, Lip GY, et al. (2014) Comparison of Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation. Stroke 45: 426-431.
51Christian T Ruf, Robert P Giugliano, Eugene Braunwald, Elaine B Hoffman, Naveen Deenadayalu, et al. (2013) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet
52Nolin TD (2010) On warfarin use in kidney disease: a therapeutic window of opportunity? Am J Kidney Dis 56: 805-808.
53Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, et al. (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366: 9-19.
54Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et al. (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295: 1519-1530.
55Deiner HC, Executive Steering Committee of the SPORTIFF III and V Investigators (2006) Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 21: 279-293.
56Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112: 1973-1979.